Verenigde Staten - Engels - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - desogestrel (unii: 81k9v7m3a3) (desogestrel - unii:81k9v7m3a3), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - desogestrel 0.15 mg - desogestrel and ethinyl estradiol tablets usp, 0.15 mg/0.03 mg are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. oral contraceptives are highly effective. table 1 lists the typical accidental pregnancy rates for users of combined oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization, the iud, and the norplant system depends upon the reliability with which they are used. correct and consistent use of these methods can result in lower failure rates. in a clinical trial with desogestrel and ethinyl estradiol tablets, 1,195 subjects completed 11,656 cycles and a total of 10 pregnancies were reported. this represents an overall user-efficacy (typical user-efficacy) pregnancy rate of 1.12 per 100 women-years. this rate includes patients who did not take the drug correctly. table 1:  percentage of women experiencing an unintended pregnancy during the first year of typical use an

Verenigde Staten - Engels - NLM (National Library of Medicine)

mayne pharma inc. - desogestrel (unii: 81k9v7m3a3) (desogestrel - unii:81k9v7m3a3), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - desogestrel and ethinyl estradiol tablets, usp are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. oral contraceptives are highly effective. table i lists the typical accidental pregnancy rates for users of combined oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization, the iud, and the norplant system depends upon the reliability with which they are used. correct and consistent use of these methods can result in lower failure rates. in a clinical trial with desogestrel and ethinyl estradiol tablets 1,195 subjects completed 11,656 cycles and a total of 10 pregnancies were reported. this represents an overall user-efficacy (typical user-efficacy) pregnancy rate of 1.12 per 100 women-years. this rate includes patients who did not take the drug correctly. emergency contraceptive pills: treatment initiated within 72 hours after unprotected intercourse reduces the risk of pregna

Verenigde Staten - Engels - NLM (National Library of Medicine)

northstar rx llc - desogestrel (unii: 81k9v7m3a3) (desogestrel - unii:81k9v7m3a3) - desogestrel 0.15 mg

Verenigde Staten - Engels - NLM (National Library of Medicine)

naari pte limited - desogestrel (unii: 81k9v7m3a3) (desogestrel - unii:81k9v7m3a3), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - desogestrel and ethinyl estradiol tablets usp 0.15 mg/0.03 mg are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. oral contraceptives are highly effective. table 1 lists the typical accidental pregnancy rates for users of combined oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization, the iud, and the norplant system depends upon the reliability with which they are used. correct and consistent use of these methods can result in lower failure rates. in a clinical trial with desogestrel and ethinyl estradiol tablets, 1,195 subjects completed 11,656 cycles and a total of 10 pregnancies were reported. this represents an overall user-efficacy (typical user-efficacy) pregnancy rate of 1.12 per 100 women-years. this rate includes patients who did not take the drug correctly. desogestrel and ethinyl estradiol tablets 0.15 mg/0.03 mg has not been studied for and is not indicated for use in emergency contraception. desogestrel and ethinyl estradiol tablets are contraindicated in females who are known to have or develop the following conditions: - thrombophlebitis or thromboembolic disorders - a past history of deep vein thrombophlebitis or thromboembolic disorders - known thrombophilic conditions - cerebral vascular or coronary artery disease (current or history) - valvular heart disease with complications - persistent blood pressure values of ≥ 160 mm hg systolic or ≥ 100 mg hg diastolic 102 - diabetes with vascular involvement - headaches with focal neurological symptoms - major surgery with prolonged immobilization - current diagnosis of, or history of, breast cancer, which may be hormone-sensitive - carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia - undiagnosed abnormal genital bleeding - cholestatic jaundice of pregnancy or jaundice with prior pill use - acute or chronic hepatocellular disease with abnormal liver function - hepatic adenomas or carcinomas - known or suspected pregnancy - hypersensitivity to any component of this product - are receiving hepatitis c drug combinations containing ombitasivir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for alt elevations (see section 5 in warnings), risk of liver enzyme elevations with concomitant hepatitis c treatment).

Verenigde Staten - Engels - NLM (National Library of Medicine)

naari pte. limited - desogestrel (unii: 81k9v7m3a3) (desogestrel - unii:81k9v7m3a3), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - desogestrel and ethinyl estradiol tablets, usp and ethinyl estradiol tablets, usp is indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception. oral contraceptives are highly effective. table ii lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. correct and consistent use of these methods can result in lower failure rates. % of women experiencing an unintended pregnancy within the first year of use % of women  continuing use at  one year a method (1) typical use b (2) perfect use c (3) (4) chance d 85 85 spermicides e 26 6 40 periodic abstinence 25 63 calendar 9 ovulation method 3 sympto-thermal f 2 post-ovulation 1 withdrawal 19 4 cap g parous women 40 26 42 nulliparous women 20 9 56 sponge parous women 40 20 42 nulliparous women 20 9 56 diaphragm g 20 6 56 condom h female (reality) 21 5 56 male 14 3 61 pill 5 71 progestin only 0.5 combined 0.1 iud progesterone t 2 1.5 81 copper t 380a 0.8 0.6 78 lng 20 0.1 0.1 81 depo-provera 0.3 0.3 70 norplant and norplant-2 0.05 0.05 88 female sterilization 0.5 0.5 100 male sterilization 0.15 0.10 100 adapted from hatcher et al., 1998, ref #1. a)  among couples attempting to avoid pregnancy, the percentage who continue to use a method for one year. b)  among typical couples who initiate use of a method (not necessarily for the first time), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason. c) among couples who initiate use of a method (not necessarily for the first time) and who use it perfectly (both consistently and correctly), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason. d)  the percents becoming pregnant in columns (2) and (3) are based on data from populations where contraception is not used and from women who cease using contraception in order to become pregnant. among such populations, about 89% become pregnant within one year. this estimate was lowered slightly (to 85%) to represent the percent who would become pregnant within one year among women now relying on reversible methods of contraception if they abandoned contraception altogether. e) foams, creams, gels, vaginal suppositories, and vaginal film. f)  cervical mucus (ovulation) method supplemented by calendar in the pre-ovulatory and basal body temperature in the post-ovulatory phases. g) with spermicidal cream or jelly. h)  without spermicides. oral contraceptives should not be used in women who currently have the following conditions: - thrombophlebitis or thromboembolic disorders - a past history of deep vein thrombophlebitis or thromboembolic disorders - cerebral vascular or coronary artery disease - current diagnosis of, or history of, breast cancer, which may be hormone-sensitive - carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia - undiagnosed abnormal genital bleeding - cholestatic jaundice of pregnancy or jaundice with prior pill use - hepatic adenomas or carcinomas - known or suspected pregnancy - are receiving hepatitis c drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for alt elevations (see warnings, risk of liver enzyme elevations with concomitant hepatitis c treatment ).

Verenigde Staten - Engels - NLM (National Library of Medicine)

remedyrepack inc. - desogestrel (unii: 81k9v7m3a3) (desogestrel - unii:81k9v7m3a3), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - desogestrel 0.1 mg - caziant (desogestrel and ethinyl estradiol tablets) is indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception. oral contraceptives are highly effective. table 2 lists the typical unintended pregnancy rates for users of combination oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization, the iud, and implants, depends upon the reliability with which they are used. correct and consistent use of these methods can result in lower failure rates. % of women experiencing an unintended pregnancy within the first year of use % of women continuing use at one year * method typical use † perfect use ‡ (1) (2) (3) (4) chance § 85 85 spermicides ¶ 26 6 40 periodic abstinence 25 63 calendar 9 ovulation method 3 sympto-thermal # 2 post-ovulation 1 withdrawal 19 4 cap Þ parous women 40 26 42 nulliparous women 20 9 56 sponge parous women 40 20 42 nulliparous women 20 9 56 diaphragm Þ 20 6 56 condom

Verenigde Staten - Engels - NLM (National Library of Medicine)

mayne pharma inc. - desogestrel (unii: 81k9v7m3a3) (desogestrel - unii:81k9v7m3a3), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - desogestrel 0.1 mg - caziant (desogestrel and ethinyl estradiol tablets) is indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception. oral contraceptives are highly effective. table 2 lists the typical unintended pregnancy rates for users of combination oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization, the iud, and implants, depends upon the reliability with which they are used. correct and consistent use of these methods can result in lower failure rates. % of women experiencing an unintended pregnancy within the first year of use % of women continuing use at one year * method typical use † perfect use ‡ (1) (2) (3) (4) chance§ 85 85 spermicides¶ 26 6 40 periodic abstinence 25 63 calendar 9 ovulation method 3 sympto-thermal# 2 post-ovulation 1 withdrawal 19 4 capÞ parous women 40 26 42 nulliparous women 20 9 56 sponge parous women 40 20 42 nulliparous women 20 9 56 diaphragmÞ 20 6 56 condomß  female

Verenigde Staten - Engels - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - desogestrel (unii: 81k9v7m3a3) (desogestrel - unii:81k9v7m3a3), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - desogestrel 0.1 mg - velivet (desogestrel and ethinyl estradiol tablets) is indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception. oral contraceptives are highly effective. table 2 lists the typical unintended pregnancy rates for users of combination oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization, the iud, and implants, depends upon the reliability with which they are used. correct and consistent use of these methods can result in lower failure rates. table 2: percentage of women experiencing an unintended pregnancy during the first year of typical use and the first year of perfect use of contraception and the percentage continuing use at the end of the first year, united states. % of women experiencing an unintended pregnancy within the first year of use % of women continuing use at one year * method typical use † perfect use ‡ (1) (2) (3) (4) chance§ 85 85 spermicides¶ 26 6 40 periodic abstinence 25

Verenigde Staten - Engels - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - desogestrel (unii: 81k9v7m3a3) (desogestrel - unii:81k9v7m3a3), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - desogestrel 0.15 mg - reclipsen™ (desogestrel and ethinyl estradiol tablets usp) is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. oral contraceptives are highly effective. table 1 lists the typical accidental pregnancy rates for users of combined oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization, the iud, and the norplant system depends upon the reliability with which they are used. correct and consistent use of these methods can result in lower failure rates. in a clinical trial with reclipsen (desogestrel and ethinyl estradiol tablets usp), 1,195 subjects completed 11,656 cycles and a total of 10 pregnancies were reported. this represents an overall user-efficacy (typical user-efficacy) pregnancy rate of 1.12 per 100 women-years. this rate includes patients who did not take the drug correctly. table 1: percentage of women experiencing an unintended pregnancy during the first year of typi

Verenigde Staten - Engels - NLM (National Library of Medicine)

physicians total care, inc. - desogestrel (unii: 81k9v7m3a3) (desogestrel - unii:81k9v7m3a3), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - desogestrel 0.1 mg - velivet™ (desogestrel and ethinyl estradiol, usp) tablets are indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception. oral contraceptives are highly effective. table ii lists the typical unintended pregnancy rates for users of combination oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization, the iud, and implants depends upon the reliability with which they are used. correct and consistent use of these methods can result in lower failure rates. 100 emergency contraceptive pills : treatment initiated within 72 hours after unprotected intercourse reduces risk of pregnancy by at least 75% lactational amenorrhea method : lam is a highly effective, temporary method of contraception. source: trussell j, stewart f, contraceptive efficacy. in hatcher ra, trussell j, stewart f, cates w, stewart gk, kowal d, guest f, contraceptive technology: seventeenth revised edition . oral contraceptives shou